The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 38 | 0.0% | 5.6% | Near average | |
Quality | 8 | -5084.1% | 7.6% | Below average | |
Safety | 33 | 0.2x | 0.4x | Below average | |
Capital Return | 93 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
20/20 Biolabs, Inc. Common Stock is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy 20/20 Biolabs, Inc. Common Stock shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
20/20 Biolabs (AIDX) stock shows a state of complete stability in analyst estimates, with the target price holding steady at 5 dollars without any change across periods (day, week, month). This consistency reflects a unified view by only one analyst covering the stock, indicating an absence of Dispersion in opinions, but at the same time highlighting the limited analytical coverage of the stock.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.